This product is an active protein and may elicit a biological response in vivo, handle with caution.
Centrifuge the vial prior to opening. Reconstitute in 10 mM Tris pH 8.0 to a concentration of 0.1-1.0 mg/ml. This solution can then be diluted into other aqueous buffers and stored at 4oC for 1 week or -20oC for future use. Repeated freeze thaw cycles will result in some loss of activity.
Androgen induced growth factor
Androgen-induced growth factor
Fibroblast growth factor 8
Fibroblast growth factor 8 (androgen induced)
Fibroblast growth factor 8 precursor
Heparin-binding growth factor 8
Stimulates growth of the cells in an autocrine manner. Mediates hormonal action on the growth of cancer cells.
Defects in FGF8 are the cause of Kallmann syndrome type 6 (KAL6) [MIM:612702]. Kallmann syndrome is a disorder that associates hypogonadotropic hypogonadism and anosmia. Anosmia or hyposmia is related to the absence or hypoplasia of the olfactory bulbs and tracts. Hypogonadism is due to deficiency in gonadotropin-releasing hormone and probably results from a failure of embryonic migration of gonadotropin-releasing hormone-synthesizing neurons. In some patients other developmental anomalies can be present, which include renal agenesis, cleft lip and/or palate, selective tooth agenesis, and bimanual synkinesis. In some cases anosmia may be absent or inconspicuous. Defects in FGF8 are a cause of idiopathic hypogonadotropic hypogonadism (IHH) [MIM:146110]. IHH is defined as a deficiency of the pituitary secretion of follicle-stimulating hormone and luteinizing hormone, which results in the impairment of pubertal maturation and of reproductive function.
Belongs to the heparin-binding growth factors family.